Abacavir is a nucleoside reverse-transcriptase inhibitor, with few drug interactions and a favorable safety profi le, therefore commonly used in combination with other antiretroviral agents as part of highly active antiretroviral treatment regimens. Approximately 5%-8% of human immunodefi ciency virus (HIV) infected patients on abacavir treatment develop a hypersensitivity reaction (HSR) which usually occurs within the fi rst 6 weeks of treatment. 1 HSR is characterized by a multisystemic involvement that becomes more severe with continuous dosing, requiring discontinuation of the drug. Subsequent rechallenge with abacavir must be avoided, since there is a high risk of developing a life threatening reaction. 2 HSR incidence varies among different populations, being more common in Caucasian patients than in those of African or Asian origin. 3 Abacavir HSR occurs in approximately 4% of Chilean HIV-infected patients (Chilean AIDS Cohort, Carlos Beltran personal communication).
Since 2002, many studies have reported a strong association between abacavir HSR and the class I human leukocyte antigen (HLA) allele B*5701. 4, 5 More so, the utility of HLA-B*5701 screening as a pharmacogenetic test to predict the risk of developing HSR has been demonstrated in abacavirnaïve HIV-infected patients. 6, 7 The incidence of HSR may vary substantially among different populations due to the heterogeneity in HLA-B*5701 prevalence across distinct ethnicities. 3, 8 Ideally, before implementing HLA-B*5701 genetic screening in a given population, its prevalence should be ascertained, particularly if it is unknown or poorly described, as in the Chilean population. Serological methods for HLA-B57 detection lack specificity and commercial molecular HLA-B typing methods used for identifying all known HLA-B alleles are expensive and laborious. Therefore the implementation of an alternate cost-effective method for HLA-B*5701 screening would be an appropriate approach to reduce the risk of developing HSR in the HIV positive patient population that is going to receive abacavir treatment. The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients after implementing a typing method for HLA-B*5701 screening.
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In order to validate the method for B*5701 typing, 28 External Quality Control DNA samples from the College of American Pathologists (CAP) HLA-typing survey (2 B*5701 positive, 26 B*57 negative), and 71 B*57 positive Chilean subjects (previously typed by a low resolution commercial method) were analyzed. To establish the B*5701 carrier frequency in Chilean general population, 300 unrelated anonymised blood bank donors (150 men and 150 women) were typed. After implementation and validation of HLA-B*5701 molecular typing for routine clinical testing, 492 HIV-positive abacavir-naïve patients were referred to our laboratory for HLA-B*5701 screening prior initiating abacavir treatment. DNA from all samples was extracted by a standard "salting out" method.
A touch down PCR was implemented using the sequence specifi c primers (SSP) and conditions described by Martin et al. 9 with minor modifi cations. The forward primer was synthesized without the M13 sequence tag, and the PCR cycling conditions were slightly different as the fi rst four cycles at 70°C annealing temperature were omitted. Also, a different target (the alpha-1-antitrypsin gen, AAT) was used as internal control of amplifi cation, using the primers AAT3 (5'-CCC ACC TTC CCC TCT CTC CAG GCA AAT GGG-3') and AAT4 (5'-GGG CCT CAG TCC CAA CAT GGC TAA GAG GTG-3') at a fi nal concentration of 2.5 µM. PCR products were subjected to electrophoresis on a 2% agarose gel stained with ethidium bromide and visualized under UV light. This multiplexed SSP-PCR allows the identifi cation of alleles carrying the generic B*57 and those with the subtype B*5701 by their amplicon sizes: the HLA-B*57 group-specifi c primer pair amplifi es a 175 bp fragment, HLA-B*5701-subtype specifi c primers a fragment of 94 bp, and the internal control primers a 360 bp fragment. Given that this method only assesses the presence or absence of B*57 and B*5701 alleles, zygosity status could not be determined by this mean. Therefore a low resolution commercial typing method (Peel-Freez®SSP-UniTray® InvitrogenTM) was used to determine homozygosity or heterozygosity in the B*5701 positive samples. Allele and carrier frequencies for HLA-B*5701 were determined by direct gene counting and the data from both populations (i.e. general population and HIV patients) were analyzed by using the Chi-square test (MINITAB®14). 10 The results obtained with the external quality control samples were 100% concordant with those reported by the CAP, and all 71 B*57 samples previously typed were correctly identifi ed by the group-specifi c primers. Thus, this SSP-PCR method was validated for routine analysis. See Figure 1 for typical results. The B*5701 allele was present in 64 of 71 (90%) B*57 positive subjects, the 7 remaining (10%) carried a different subtype. In the general population, from a total of 300 subjects analyzed, 14 individuals (4.7 %) carried a B*57 allele, from which 11 (3.7 %) were B*5701, and 3 (1.0%) had another subtype. The remaining 286 were negative for the Table 1 . The observed B*5701 carrier and allele frequencies were higher in the general population sample than in HIV-infected patients. The statistical analysis performed using the Chi-square test to determine if this difference between both populations was noteworthy, revealed that it was not signifi cant (p < 0.05).
A prospective screening genetic test should fulfi ll several requirements before its introduction into routine clinical practice, such as: improve the clinical outcome, have high predictive values, be cost-effective, and easy to implement technically. 3 The clinical utility of B*5701 screening is well demonstrated, so technical aspects and feasibility of an analysis method were important to be evaluated. The PCR-based technique implemented here for HLA-B*5701 screening proved to be 100% sensitive in detecting B*5701 and B*57 positive alleles. It was also a method easy to implement and to validate, as well as technically simple to perform in a clinical routine setting. More so, an "in house" PCR, properly validated as this one, allows cost reduction when compared to commercial kits, thus allowing its use also in developing countries where less fi nancial and technical resources are available.
The observed B*5701 carrier frequency (3.7%) in this general population sample from Chile is in agreement with data (4.0%) from 70 Chilean individuals published at the "allele frequencies in worldwide populations" database. 11 However, in this database there is no information about the status of those Chilean individuals (i.e. patients, controls or general population). Also, the B*57 carrier frequency published therein (1.0%) is much different than the one observed by us (4.7%), and unlikely to be correct, since the generic type of an allele cannot have a lower frequency than one of its subtypes. The fact that the B*5701 frequencies we observed in the general population and in the patient population samples are lower than the ones reported for Caucasians and higher than those in populations of Asian origin, is most likely due to our mixed genetic background of Caucasian and Native American of mongoloid ancestry. 12, 13 To our knowledge, there are no B*5701 carrier or allele frequencies described for HIV-positive patients from other Latin American countries, except for Hispanics in the United States. 3 The carrier frequency found in our HIV-infected patients (2.2%) and in Chilean general population (3.7%) were very similar to the ones reported for US-Hispanics. 8 The difference between HIV-infected patients and general population, although not statistically significant, could probably be related to the finding that HLA-B*5701 carriage has been associated with slow progression of HIV infection, therefore less patients carrying a HLA-B*5701 allele would require antiretroviral therapy and thus B*5701 typing. 14, 15 Considering the vast evidence on the benefits of B*5701 screening, its prevalence in the Chilean general population, and the availability of a proper screening method, B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended. 
